Starling Oncology STLNW
NASDAQ STLNW
$0.04 -0.01 (-21.32%)
As of: Sep 9, 2026 · 12:49 PM EDT

Starling Oncology (STLNW) Non-Current Deffered Revenue (2020 - 2021)

Starling Oncology's (STLNW) quarterly Non-Current Deffered Revenue came in at $6.3 million in Q3 2021, little changed on a YoY basis from $6.3 million in Q3 2020, and little changed quarter-over-quarter from $6.3 million in Q2 2021.

Analysis

Starling Oncology (STLNW) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends

Starling Oncology (STLNW) has reported Non-Current Deffered Revenue for 2 consecutive years, with $6.3 million the latest figure, recorded in Q3 2021.

  • For the quarter ending Q3 2021, Non-Current Deffered Revenue changed 0.0% year-over-year to $6.3 million; the trailing twelve-month figure through Sep 2021 stood at $6.3 million (changed 0.0% YoY), and the FY2020 full-year result was $6.3 million, changed N/A from the prior year.
  • Non-Current Deffered Revenue steadied at $6.3 million in Q3 2021 per STLNW's latest filing, from $6.3 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $6.3 million in Q1 2020 and bottomed at $6.3 million in Q1 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Davita 11.90 Bn 11.22 Bn 1.16 Bn -
2 RadNet 5.52 Bn 4.79 Bn 88.08 Mn -
3 Fresenius Medical Care AG 4.79 Bn 4.09 Bn 1.52 Bn -
4 Concentra Group Holdings Parent 4.26 Bn 4.10 Bn 192.10 Mn -
5 Privia Health 2.57 Bn 2.15 Bn - -
6 Pediatrix Medical 2.15 Bn 1.74 Bn - -
7 Progyny 2.11 Bn 1.87 Bn 89.30 Mn -
8 Surgery Partners 1.84 Bn 1.63 Bn 622.10 Mn -
9 U S Physical Therapy 1.17 Bn 1.15 Bn 41.94 Mn -
10 Starling Oncology 4.13 Mn -36.96 Mn 27.17 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 6.30 Mn
Jun 30, 2021 6.30 Mn
Mar 31, 2021 6.30 Mn
Dec 31, 2020 6.30 Mn
Sep 30, 2020 6.30 Mn
Jun 30, 2020 6.30 Mn
Mar 13, 2020 6.30 Mn